Edition:
United Kingdom

Conatus Pharmaceuticals Inc (CNAT.OQ)

CNAT.OQ on NASDAQ Stock Exchange Global Market

0.86USD
21 May 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$0.86
Open
--
Day's High
--
Day's Low
--
Volume
200
Avg. Vol
162,065
52-wk High
$6.73
52-wk Low
$0.69

About

Conatus Pharmaceuticals Inc. is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active... (more)

Overall

Beta: 1.29
Market Cap(Mil.): $174.93
Shares Outstanding(Mil.): 30.00
Dividend: --
Yield (%): --

Financials

  CNAT.OQ Industry Sector
P/E (TTM): -- 69.30 32.55
EPS (TTM): -0.99 -- --
ROI: -53.65 8.91 13.82
ROE: -80.58 10.05 15.24

BRIEF-Conatus Completes Enrollment In Phase 2B Clinical Trial Of Emricasan In Patients With Decompensated Nash Cirrhosis

* CONATUS ANNOUNCES COMPLETION OF ENROLLMENT IN ENCORE-LF PHASE 2B CLINICAL TRIAL OF EMRICASAN IN PATIENTS WITH DECOMPENSATED NASH CIRRHOSIS

12 Feb 2019

Earnings vs. Estimates